Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers.

The broad spectrum of irAEs and the onset time of irAEs are important challenges of therapy with ICIs, requiring proactive monitoring and tailored management strategies to optimize the safety and efficacy of immunotherapy.